Oncuria®, Multiplex Biomarker Immunoassay for Bladder Cancer, Urine
Bladder cancer is the fourth leading cause of cancer death in older patients in the United States. The urothelial (transitional) cell carcinoma of bladder is the most common bladder cancer, accounting for approximately 90% of cases. Nonurothelial bladder cancers are less common with the lower prevalence and include squamous cell carcinoma and adenocarcinoma. Painless hematuria is the most common presenting sign of bladder cancer. Early detection of bladder cancer is very important for diagnosis, treatment and disease management in order to improve recovery and survival rates.
Currently, cystoscopy is the gold standard tool for bladder cancer detection and diagnosis, however, this procedure is expensive and invasive. There is a search for noninvasive testing to reduce the unnecessary cystoscopy for the patient who is less likely to have bladder cancer. Although voided urine cytology is still a commonly used noninvasive method for detecting bladder cancer, its sensitivity is very low ranging from 30 to 50%, especially for low grade urothelial carcinoma.
Oncuria™ is a noninvasive urine-based test for early diagnosis and management of bladder cancer. Oncuria™ uses a multiplex immunoassay to determine the concentration of 10 proteins (alpha-1 antitrypsin, A1AT; Angiogenin, ANG; apolipoprotein E, APOE; carbonic anhydrase 9, CA9; interleukin 8, IL8; matrix metallopeptidase 9, MMP9; matrix metallopeptidase 10, MMP10; plasminogen activator inhibitor 1, PAI1; syndecan 1, SDC1; and vascular endothelial growth factor A, VEGFA) associated with bladder cancer, from a single voided urine sample. The probability is calculated from an algorithm that is composed of the weighted value of these 10 proteins, along with the weighted value for age, gender, and race. The result ranges from 0 to 100%, with a cutoff value of 46.76% 0.179.
Oncuria™ can be also used for predicting response in patients recently diagnosed with non-muscle invasive bladder cancer who have had their tumor transurethrally resected and are to begin intravesical BCG (Bacillus Calmette-Guerin) therapy. The result ranges from 0 to 1.00, with a cutoff value of 0.179.
- Early detection of bladder cancer in patients presenting with hematuria
- Monitoring patients with non–muscle-invasive or muscle-invasive bladder cancer for recurrence
- Predicting whether patients with intermediate- to high-risk, early-stage bladder cancer will respond to bacillus Calmette-Guérin (BCG)
The algorithm score based on results for 10 biomarkers and other multiples is used to establish the cutoff based on study.
- The score for Detect and Monitor is 0%-100%, with the cutoff of 46,76%.
- The lower the score, the lower risk for bladder cancer.
The score for Predict is 0.1-1.00, with the cutoff of 0.179. Low probability of BCG success - Negative - if the score <0.179
For Detect and Monitor: < 46,76%.
For Predict: 0.179
Midstream voided urine collected in a sterile specimen container.
Stability
Single void of urine should be collected by the patient or medical personnel into a sterile container using aseptic conditions. Within 30-60 minutes of collection specimen should be store at 2-8°C.
Samples may be stored at 2-8°C for up to 1 week prior to testing.
Alternatively, samples may be stored at -20°C or lower and stored up to 8 weeks. For storage longer than 8 weeks, -80°C is required.
- Physician. 2017 Oct 15;96(8):507-514. [PMID: 29094888]
- JAMA. 2020 Nov 17;324(19):1980-1991. [PMID: 33201207]
- Pract Lab Med. 2020 Nov 13;22:e00189. [PMID: 33294574]
- J Transl Med. 2021 Apr 6;19(1):141. [PMID: 33823873]
- Cancer Biomark. 2022;33(1):151-157. [PMID: 34511488]